Q-omics provides the consensus-scored BTF3P8 profile across patient tissues and cancer cell-line models. BTF3P8 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, BTF3P8 is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, BTF3P8 RNA expression shows 12,123 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight OV, STAD, and GBM as cancer lineages where BTF3P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTF3P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTF3P8 survival associations across molecular data types. BTF3P8 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTF3P8 RNA expression–survival associations across cancer types. High BTF3P8 expression shows unfavorable associations in OV, STAD and LIHC, but favorable associations in CESC, KIRC and MESO. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify OV as the clearest survival context for BTF3P8 RNA expression.
This table summarizes BTF3P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for BTF3P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTF3P8 shows lower tumor expression in STAD and higher tumor expression in LUAD and KIRC. The STAD box plot shows higher BTF3P8 RNA expression in normal versus tumor tissue (log2 FC = −0.224, t-test p = .002).
This table shows molecular features associated with BTF3P8 in patient tissues and cancer cell lines. In patient samples, BTF3P8 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
